Checkpoint Historical Balance Sheet

CKPT Stock

USD 4.03 0.28 7.47%

Trend analysis of Checkpoint Therapeutics balance sheet accounts such as Other Current Liab of 6.3 M, Total Current Liabilities of 12.9 M or Other Liab of 0.0 provides information on Checkpoint Therapeutics' total assets, liabilities, and equity, which is the actual value of Checkpoint Therapeutics to its prevalent stockholders. By breaking down trends over time using Checkpoint Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Checkpoint Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Checkpoint Therapeutics is a good buy for the upcoming year.

Checkpoint Therapeutics Inventory

0.88

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Checkpoint Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy Checkpoint Stock please use our How to Invest in Checkpoint Therapeutics guide.

About Checkpoint Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Checkpoint Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Checkpoint Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Checkpoint Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Checkpoint currently owns. An asset can also be divided into two categories, current and non-current.

Checkpoint Therapeutics Balance Sheet Chart

At this time, Checkpoint Therapeutics' Accounts Payable is comparatively stable compared to the past year. Common Stock Total Equity is likely to gain to about 10.9 K in 2024, whereas Total Current Liabilities is likely to drop slightly above 12.9 M in 2024.

Common Stock Shares Outstanding Short Long Term Debt Total Cash And Short Term Investments Long Term Debt Total

Add Fundamental

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Checkpoint Therapeutics balance sheet. This account contains Checkpoint Therapeutics investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Checkpoint Therapeutics fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Most accounts from Checkpoint Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Checkpoint Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Checkpoint Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy Checkpoint Stock please use our How to Invest in Checkpoint Therapeutics guide.At this time, Checkpoint Therapeutics' Accounts Payable is comparatively stable compared to the past year. Common Stock Total Equity is likely to gain to about 10.9 K in 2024, whereas Total Current Liabilities is likely to drop slightly above 12.9 M in 2024.

Checkpoint Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Net Receivables	Common Stock Total Equity	Retained Earnings Total Equity	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Short Long Term Debt Total	Net Debt	Cash And Short Term Investments	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse
Total Assets		0.1	0.28	0.86	0.73	-0.12	0.44	1.0	0.22	0.31	-0.38	-0.61	0.68	0.46	0.35	0.31	0.63	1.0	0.63	0.75	0.26	-0.17	0.13	0.26	0.33	0.27
Other Current Liab	0.1		0.95	-0.39	0.47	-0.83	0.68	0.1	-0.12	0.79	-0.84	0.3	0.53	0.38	0.85	0.94	0.53	0.1	0.53	0.27	-0.25	0.57	-0.59	-0.25	0.72	0.87
Total Current Liabilities	0.28	0.95		-0.24	0.5	-0.83	0.88	0.27	0.07	0.83	-0.9	0.18	0.63	0.49	0.87	1.0	0.63	0.28	0.63	0.48	-0.23	0.52	-0.55	-0.23	0.73	0.88
Total Stockholder Equity	0.86	-0.39	-0.24		0.46	0.34	-0.01	0.87	0.19	-0.14	0.1	-0.74	0.35	0.22	-0.11	-0.21	0.29	0.86	0.29	0.51	0.43	-0.46	0.44	0.43	-0.03	-0.18
Net Tangible Assets	0.73	0.47	0.5	0.46		-0.57	0.41	0.74	0.04	0.67	-0.65	-0.12	0.86	0.35	0.69	0.54	0.85	0.73	0.85	0.58	-0.24	0.34	-0.36	-0.24	0.27	0.56
Retained Earnings	-0.12	-0.83	-0.83	0.34	-0.57		-0.67	-0.11	0.07	-0.98	0.94	-0.52	-0.66	-0.39	-0.93	-0.83	-0.71	-0.12	-0.71	-0.51	0.66	-0.74	0.76	0.66	-0.37	-0.89
Accounts Payable	0.44	0.68	0.88	-0.01	0.41	-0.67		0.42	0.39	0.71	-0.8	-0.04	0.67	0.61	0.72	0.88	0.66	0.44	0.66	0.64	-0.16	0.42	-0.45	-0.16	0.54	0.7
Cash	1.0	0.1	0.27	0.87	0.74	-0.11	0.42		0.19	0.31	-0.37	-0.6	0.67	0.43	0.34	0.3	0.62	1.0	0.62	0.74	0.26	-0.19	0.15	0.26	0.33	0.26
Net Receivables	0.22	-0.12	0.07	0.19	0.04	0.07	0.39	0.19		-0.03	0.01	-0.44	0.34	0.29	-0.01	0.07	0.31	0.22	0.31	0.13	0.12	0.25	-0.26	0.12	-0.28	-0.12
Common Stock Total Equity	0.31	0.79	0.83	-0.14	0.67	-0.98	0.71	0.31	-0.03		-0.98	0.37	0.76	0.48	0.94	0.83	0.81	0.31	0.81	0.67	-0.6	0.68	-0.7	-0.6	0.41	0.89
Retained Earnings Total Equity	-0.38	-0.84	-0.9	0.1	-0.65	0.94	-0.8	-0.37	0.01	-0.98		-0.26	-0.76	-0.57	-0.96	-0.9	-0.79	-0.38	-0.79	-0.7	0.44	-0.6	0.63	0.44	-0.55	-0.93
Common Stock Shares Outstanding	-0.61	0.3	0.18	-0.74	-0.12	-0.52	-0.04	-0.6	-0.44	0.37	-0.26		-0.23	-0.37	0.27	0.17	-0.12	-0.61	-0.12	-0.19	-0.77	0.34	-0.32	-0.77	-0.06	0.34
Inventory	0.68	0.53	0.63	0.35	0.86	-0.66	0.67	0.67	0.34	0.76	-0.76	-0.23		0.65	0.78	0.65	0.99	0.68	0.99	0.71	-0.23	0.6	-0.63	-0.23	0.2	0.63
Other Current Assets	0.46	0.38	0.49	0.22	0.35	-0.39	0.61	0.43	0.29	0.48	-0.57	-0.37	0.65		0.52	0.48	0.62	0.46	0.62	0.62	0.1	0.39	-0.42	0.1	0.31	0.46
Other Stockholder Equity	0.35	0.85	0.87	-0.11	0.69	-0.93	0.72	0.34	-0.01	0.94	-0.96	0.27	0.78	0.52		0.87	0.77	0.35	0.77	0.62	-0.38	0.62	-0.65	-0.38	0.48	0.97
Total Liab	0.31	0.94	1.0	-0.21	0.54	-0.83	0.88	0.3	0.07	0.83	-0.9	0.17	0.65	0.48	0.87		0.65	0.31	0.65	0.48	-0.23	0.52	-0.54	-0.23	0.73	0.87
Short Long Term Debt	0.63	0.53	0.63	0.29	0.85	-0.71	0.66	0.62	0.31	0.81	-0.79	-0.12	0.99	0.62	0.77	0.65		0.63	1.0	0.71	-0.37	0.65	-0.68	-0.37	0.16	0.62
Total Current Assets	1.0	0.1	0.28	0.86	0.73	-0.12	0.44	1.0	0.22	0.31	-0.38	-0.61	0.68	0.46	0.35	0.31	0.63		0.63	0.75	0.26	-0.17	0.13	0.26	0.33	0.27
Short Term Debt	0.63	0.53	0.63	0.29	0.85	-0.71	0.66	0.62	0.31	0.81	-0.79	-0.12	0.99	0.62	0.77	0.65	1.0	0.63		0.71	-0.37	0.65	-0.68	-0.37	0.16	0.62
Common Stock	0.75	0.27	0.48	0.51	0.58	-0.51	0.64	0.74	0.13	0.67	-0.7	-0.19	0.71	0.62	0.62	0.48	0.71	0.75	0.71		-0.13	0.14	-0.19	-0.13	0.31	0.58
Short Long Term Debt Total	0.26	-0.25	-0.23	0.43	-0.24	0.66	-0.16	0.26	0.12	-0.6	0.44	-0.77	-0.23	0.1	-0.38	-0.23	-0.37	0.26	-0.37	-0.13		-0.63	0.63	1.0	0.26	-0.31
Net Debt	-0.17	0.57	0.52	-0.46	0.34	-0.74	0.42	-0.19	0.25	0.68	-0.6	0.34	0.6	0.39	0.62	0.52	0.65	-0.17	0.65	0.14	-0.63		-1.0	-0.63	-0.1	0.49
Cash And Short Term Investments	0.13	-0.59	-0.55	0.44	-0.36	0.76	-0.45	0.15	-0.26	-0.7	0.63	-0.32	-0.63	-0.42	-0.65	-0.54	-0.68	0.13	-0.68	-0.19	0.63	-1.0		0.63	0.08	-0.52
Long Term Debt Total	0.26	-0.25	-0.23	0.43	-0.24	0.66	-0.16	0.26	0.12	-0.6	0.44	-0.77	-0.23	0.1	-0.38	-0.23	-0.37	0.26	-0.37	-0.13	1.0	-0.63	0.63		0.26	-0.31
Non Current Liabilities Total	0.33	0.72	0.73	-0.03	0.27	-0.37	0.54	0.33	-0.28	0.41	-0.55	-0.06	0.2	0.31	0.48	0.73	0.16	0.33	0.16	0.31	0.26	-0.1	0.08	0.26		0.59
Capital Surpluse	0.27	0.87	0.88	-0.18	0.56	-0.89	0.7	0.26	-0.12	0.89	-0.93	0.34	0.63	0.46	0.97	0.87	0.62	0.27	0.62	0.58	-0.31	0.49	-0.52	-0.31	0.59

Click cells to compare fundamentals

Checkpoint Therapeutics Account Relationship Matchups

Checkpoint Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	27.0M	42.6M	55.7M	13.3M	5.4M	5.1M
Other Current Liab	4.2M	3.8M	9.8M	21.2M	11.9M	6.3M
Total Current Liabilities	8.1M	7.2M	26.0M	32.8M	18.4M	12.9M
Total Stockholder Equity	18.8M	35.4M	29.7M	(19.5M)	(13.0M)	(12.4M)
Net Tangible Assets	11.8M	18.8M	35.4M	29.7M	34.2M	26.1M
Retained Earnings	(120.1M)	(143.2M)	(199.9M)	(262.5M)	(314.3M)	(298.6M)
Accounts Payable	3.9M	3.4M	16.1M	11.5M	6.6M	7.2M
Cash	26.1M	40.8M	54.7M	12.1M	4.9M	4.7M
Net Receivables	26K	20K	17K	73K	65.7K	62.4K
Common Stock Total Equity	4K	6K	7K	9K	10.4K	10.9K
Retained Earnings Total Equity	(95.4M)	(120.1M)	(143.2M)	(199.9M)	(179.9M)	(170.9M)
Common Stock Shares Outstanding	3.5M	5.6M	7.6M	8.8M	18.7M	19.7M
Other Current Assets	863K	1.8M	976K	1.1M	450K	427.5K
Other Stockholder Equity	136.4M	173.9M	216.4M	243.0M	301.3M	150.7M
Total Liab	8.1M	7.2M	26.0M	32.8M	18.4M	13.2M
Total Current Assets	27.0M	42.6M	55.7M	13.3M	5.4M	5.1M
Accumulated Other Comprehensive Income	2.5M	4.6M	6.6M	1.9M	3.4M	3.3M
Common Stock	4K	6K	7K	9K	1K	4.2K
Net Debt	(26.1M)	(40.8M)	(54.7M)	(12.1M)	(4.9M)	(5.2M)
Cash And Short Term Investments	26.1M	40.8M	54.7M	12.1M	4.9M	4.7M
Liabilities And Stockholders Equity	27.0M	42.6M	55.7M	13.3M	5.4M	5.1M
Capital Surpluse	107.2M	139.0M	173.9M	223.0M	256.5M	133.0M
Net Invested Capital	18.8M	35.4M	29.7M	(19.5M)	(13.0M)	(12.4M)
Net Working Capital	18.8M	35.4M	29.7M	(19.5M)	(13.0M)	(12.4M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Checkpoint Stock Analysis

When running Checkpoint Therapeutics' price analysis, check to measure Checkpoint Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Checkpoint Therapeutics is operating at the current time. Most of Checkpoint Therapeutics' value examination focuses on studying past and present price action to predict the probability of Checkpoint Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Checkpoint Therapeutics' price. Additionally, you may evaluate how the addition of Checkpoint Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Checkpoint Historical Balance Sheet

Checkpoint Therapeutics Inventory

0.88

About Checkpoint Balance Sheet Analysis

Checkpoint Therapeutics Balance Sheet Chart

Common Stock Shares Outstanding

Cash And Short Term Investments

Checkpoint Therapeutics balance sheet Correlations

Checkpoint Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Checkpoint Therapeutics balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Checkpoint Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Total Current Assets	+ 1.0	Cash
Short Term Debt	+ 1.0	Short Long Term Debt
Long Term Debt Total	+ 1.0	Short Long Term Debt Total

Cash And Short Term Investments	- 1.0	Net Debt
Retained Earnings Total Equity	- 0.98	Common Stock Total Equity
Common Stock Total Equity	- 0.98	Retained Earnings
Other Stockholder Equity	- 0.96	Retained Earnings Total Equity
Capital Surpluse	- 0.93	Retained Earnings Total Equity
Other Stockholder Equity	- 0.93	Retained Earnings